Gonadotropin-releasing hormone analogs and prostatic cancer (Q39485322)

12 September 2017

1 reference

title

Gonadotropin-releasing hormone analogs and prostatic cancer (English)

1 reference

12 September 2017

Swanson LJ

1 reference

12 September 2017

Seely JH

series ordinal

1 reference

12 September 2017

Garnick MB

series ordinal

1 reference

12 September 2017

publication date

1 January 1988

1 reference

Critical Reviews in Oncology Hematology

12 September 2017

published in

1 reference

12 September 2017

1 reference

12 September 2017

1 reference

12 September 2017

page(s)

1-26

1 reference

Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Review: prostate cancer epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

1 reference

7 January 2021

FSH-releasing hormone and LH-releasing hormone.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Clinical applications of LHRH and its analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Gonadotropin-Releasing Hormone Agonist Analog- Induced Steroidogenic Lesion in the Neonatal Rat Testis: Evidence for Direct Gonadal Action*

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Buserelin as primary therapy in advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Chemotherapy Programs of the National Prostatic Cancer Project (NPCP)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Testicular histology following chronic gonadotropin-releasing hormone agonist treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Absence of a direct inhibitory effect of the gonadotropin-releasing hormone (GnRH) agonist D-Ser (TBU)6, des-Gly-NH2(10) GnRH ethylamide (Buserelin) on testicular steroidogenesis in men

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Absence of gonadotropin-releasing hormone receptors in human gonadal tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2888%2980003-9

7 January 2021

10.1016/S1040-8428(88)80003-9

Identifiers

DOI

1 reference

12 September 2017

1 reference